Skip to main content

Non-Small Cell Lung Cancer Clinical Trials

Review the non-small cell lung cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 351-375 of 528

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
MOv19-BBz CAR T Cells for the Treatment of Folate Receptor Alpha Positive Metastatic and Recurrent Non-small Cell Lung Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Nivolumab in Combination with Lymphodepletion Chemotherapy, CD40L-Augmented Tumor Infiltrating Lymphocytes, and Interleukin-2 for the Treatment of Recurrent/Refractory Stage IV Non-small Cell Lung Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Pooled Mutant KRAS-Targeted Long Peptide Vaccine in Combination with Nivolumab and Ipilimumab for the Treatment of Locally Advanced, Unresectable or Metastatic KRAS Mutated Non-small Cell Lung Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Intravenous and Intrathecal Nivolumab or Nivolumab/Relatlimab in Treating Patients with Leptomeningeal Disease
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
TROP2-CAR-NK for the Treatment of Patients with Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
KK-LC-1 TCR T Cells for the Treatment of Metastatic Gastric, Lung, Breast, and Cervical Cancers
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Status: Active
Location: 2 locations
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Status: Active
Location: 3 locations
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Status: Active
Location: 3 locations
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland